Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 3/20 | 0.59 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15591342 | 0.83 | PTGER4 (0.61) | TACR3PTGER4PTGER2HPGDALDH1A1 | |
| SCHEMBL16566678 | 0.79 | PTGER4 (0.57) | TACR3PTGER4PTGER2HPGDALDH1A1 | |
| SCHEMBL13611924 | 0.79 | PTGER4 (0.57) | TACR3PTGER4PTGER2HPGDNPC1 | |
| SCHEMBL19328605 | 0.79 | PTGER4 (0.64) | TACR3PTGER4PTGER2NPC1SMN1; SMN2 | |
| SCHEMBL13626644 | 0.78 | HPGD (0.47) | BRD4HPGDNPC1ALDH1A1IP6K1 | |
| SCHEMBL2117675 | 0.78 | PLK1 (0.66) | BRD4HPGDNPC1ALDH1A1 | |
| SCHEMBL1943712 | 0.77 | PTGER4 (0.58) | TACR3PTGER4HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL10763660 | 0.77 | HPGD (0.54) | TACR3PTGER4HPGDNPC1ALDH1A1 | |
| SCHEMBL10672864 | 0.77 | CDC25B (0.57) | TACR3PTGER4HPGDNPC1ALDH1A1 | |
| SCHEMBL12391548 | 0.76 | PTGER4 (0.47) | PTGER4HPGDNPC1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291998-A1 | EPONEMYCIN AND EPOXOMICIN ANALOGS AND USES THEREOF | EISAI R&D MANAGEMENT CO., LTD. | 2009-11-26 | — | — | US | disclosed |
| US-7524883-B2 | Eponemycin and epoxomicin analogs and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291998-A1 | EPONEMYCIN AND EPOXOMICIN ANALOGS AND USES THEREOF | PSMC4, PSMB6, EPOR | TACR3 4029/4885PTGER4 915/4885BRD4 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.